 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Allogene Therapeutics
ALLO
conference date: March 14, 2024 @
| 2019 | |||
| Allogene Therapeutics Q4 2023 |
|||
| Mar. 14, 2024 | |||
Allogene Therapeutics (ALLO) is a clinical-stage biotechnology company specializing in second-generation CAR T therapies.
, Bought initial shares on 4/24/2024
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CLDX |
| CDTX |
| GILD |
| GLYC |
| ILMN |
| IMGN |
| INCY |
| INKT |
| INO |
| IONS |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SAGE |
| SANA |
| SYRS |
| TSVT |
| VSTM |
| VRTX |
| WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers